Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1Endocrine 1Dermatologic 1CNS 1

Conditions

Neoplasm Metastasis 2Uveal Melanoma 1Sarcoma 1Rhabdomyosarcoma 1Retinoblastoma 1Pituitary Diseases 1Osteosarcoma 1Neuroblastoma 1Neoplasms 1Mesothelioma 1Melanoma 1Medulloblastoma 1Laryngeal Diseases 1Glioma 1Adenoma, Islet Cell 1

Interventions

Temozolomide 88Bevacizumab 49Radiotherapy 36Irinotecan 22Magnetic Resonance Spectroscopy 21Surgical Procedures, Operative 17Carboplatin 17Carmustine 15Radiation 13Nivolumab 11IL13-PE38 8Erlotinib Hydrochloride 8Thalidomide 7Radiotherapy, Intensity-Modulated 7Lomustine 7Imatinib Mesylate 7Everolimus 7Aminolevulinic Acid 7sargramostim 6Topotecan 6O(6)-benzylguanine 6Cyclophosphamide 6Chemotherapy, Adjuvant 6vandetanib 5temsirolimus 5fluorodopa F 18 5Vincristine 5Surveys and Questionnaires 5Radiosurgery 5Flucytosine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Glioma × LY2940680 × Clear all
NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Endeavor Biomedicines, Inc.

Phase 2 Completed
20 enrolled
CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡